DESTINY-PANTUMOUR04
Key facts
- Where
- Birmingham, Boulder, Bullhead City, Canton, Casa Grande, Coral Springs, Dallas, Decatur, Durham, Farmington, Maumee, Nashville, Philadelphia, San Diego, St. Petersburg, Topeka, West Palm Beach, and Wilson, United StatesSee the 18 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Where in United States
- BirminghamBirmingham, United StatesTaking people
- BoulderBoulder, United StatesTaking people
- Bullhead CityBullhead City, United StatesTaking people
- CantonCanton, United StatesTaking people
- Casa GrandeCasa Grande, United StatesTaking people
- Coral SpringsCoral Springs, United StatesTaking people
- DallasDallas, United StatesTaking people
- DecaturDecatur, United StatesTaking people
- DurhamDurham, United StatesTaking people
- FarmingtonFarmington, United StatesTaking people
- MaumeeMaumee, United StatesTaking people
- NashvilleNashville, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- St. PetersburgSt. Petersburg, United StatesTaking people
- TopekaTopeka, United StatesTaking people
- West Palm BeachWest Palm Beach, United StatesTaking people
- WilsonWilson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07124000
- Record updated
- 25 September 2026
- Original description
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the USRead full original descriptionShow less
Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Inclusion: Adults aged ≥18 years; Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors); A clinician decision has been made for treatment with T-DXd in accordance with the FDA label; HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent; Patients who are willing and able to provide a signed and dated informed consent.
Exclusion: Prior T-DXd therapy; Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd; Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies; Patient is participating in a clinical trial at time of enrolment.